Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 17/20 | 0.67 |
| ▸ | PGR | P06401 | 13/20 | 0.67 |
| ▸ | NR3C2 | P08235 | 10/20 | 0.67 |
| ▸ | AR | P10275 | 2/20 | 0.62 |
| ▸ | PDK1 | Q15118 | 2/20 | 0.48 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.48 |
| ▸ | PDK3 | Q15120 | 2/20 | 0.48 |
| ▸ | PDK4 | Q16654 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6691998 | 0.92 | NR3C1 (0.63) | NR3C1PGRNR3C2ARPDK1 | |
| SCHEMBL292969 | 0.90 | NR3C1 (0.65) | NR3C1PGRNR3C2AR | |
| SCHEMBL291428 | 0.88 | NR3C1 (0.64) | NR3C1PGRNR3C2ARPDK1 | |
| SCHEMBL291720 | 0.88 | NR3C1 (0.64) | NR3C1PGRNR3C2AR | |
| SCHEMBL291836 | 0.88 | NR3C1 (0.64) | NR3C1PGRNR3C2AR | |
| SCHEMBL6688411 | 0.87 | NR3C1 (0.61) | NR3C1PGRNR3C2AR | |
| SCHEMBL290544 | 0.87 | NR3C1 (0.62) | NR3C1PGRNR3C2AR | |
| SCHEMBL292680 | 0.87 | NR3C1 (0.62) | NR3C1PGRNR3C2AR | |
| SCHEMBL291377 | 0.87 | NR3C1 (0.62) | NR3C1PGRNR3C2AR | |
| SCHEMBL6686671 | 0.86 | NR3C1 (0.68) | NR3C1PGRNR3C2AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040224992-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2004-11-11 | — | — | US | claimed |
| WO-2004075864-A2 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2004-09-10 | — | — | WO | claimed |
| US-20040224992-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2004-11-11 | — | — | US | disclosed |
| WO-2004075864-A2 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2004-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040224992-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | NR3C1, NR3C2, MC2R | NR3C1 1/4885PGR 173/4885NR3C2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.